Erin Smith
Payments from drug & device makers
What this record shows
This record is dominated by grants: $11,250 of the $13,470 with a category attached, or 83.5%. Medtronic accounts for 86.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $11,337 and has fallen 99.1% since, to $104 in 2025.
Across 31 payments — averaging $434.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Boston Scientific$1K
- TG Therapeutics, Inc.$140
- EMD Serono, Inc.$119
- Acorda Therapeutics, Inc$87
- Amneal Pharmaceuticals LLC$65
- plus $35 from 2 others
Across 12 payments — averaging $3781.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz Pharmaceuticals, LLC$45K
What the payments were for
- Grants$11,25084%
- Travel & lodging$1,2009%
- Food & beverage$1,0208%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 14 | $11,639 |
| Boston Scientific | 5 | $1,384 |
| TG Therapeutics, Inc. | 7 | $140 |
| EMD Serono, Inc. | 1 | $119 |
| Acorda Therapeutics, Inc | 1 | $87 |
| Amneal Pharmaceuticals LLC | 1 | $65 |
| MDD US Operations, LLC | 1 | $22 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,470 in reported general payments places this provider in the 85th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 111 | $527,023 |
| RytaryCarbidopa/Levodopa | 341 | $453,525 |
| GocovriAmantadine Hcl | 23 | $83,535 |
| AustedoDeutetrabenazine | 12 | $82,521 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,222 | $48,220 |
| InbrijaLevodopa | 25 | $38,352 |
| NeuproRotigotine | 20 | $21,986 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $21,534 |
| Rasagiline Mesylate | 107 | $19,709 |
| AmantadineAmantadine Hcl | 319 | $16,926 |
| UbrelvyUbrogepant | 11 | $16,915 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 191 | $9,832 |
| Selegiline Hcl | 84 | $6,806 |
| Droxidopa | 27 | $5,743 |
| Midodrine Hcl | 59 | $3,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $65 | $453,525341 claims |
| MDD US Operations, LLCGocovri | $22 | $83,53523 claims |
| Acorda Therapeutics, IncInbrija | $87 | $38,35225 claims |
| AbbVieUbrelvy | $13 | $16,91511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 neurology providers in Nebraska.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Abhishek SinghOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.